Collagen products company CollPlant Holdings Ltd. (TASE: CLPT) saw its share price rise sharply on the Tel Aviv Stock exchange today after announcing positive final results of a trial for a preparation it has developed for healing and closing chronic wounds.
The trial for Vergenix FG covered 20 patients and was carried out at several wound clinics of health funds in Israel. The final results of the trial demonstrate that Vergenix FG is safe and efficacious in use on humans. In fifteen of the twenty patients treated the final results showed between 70% and 100% closure of the wound, with full closure of the wound observed in nine of the twenty patients after only four weeks.
In August this year, CollPlant submitted its CE Technical File to the European Notified Body to obtain CE Marking for Vergenix FG. The target market for the gel that the company has developed is estimated at $5 billion.
CollPlant CEO Yehiel Tal said, "We are very pleased with the final results of the trial. This is a significant stage on the way to commercialization of CollPlant's unique products, and the trial results demonstrate several material advantages of Vergenix FG, chiefly the rapid closure of the wound achieved with a single treatment. CollPlant is currently engaged in setting up the infrastructure for sales in Europe, which are planned to start as soon as European marketing approval is obtained."
Published by Globes [online], Israel business news - www.globes-online.com - on November 26, 2015
© Copyright of Globes Publisher Itonut (1983) Ltd. 2015